Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by Sonny7on Jan 12, 2021 2:45pm
177 Views
Post# 32277759

RE:RE:RE:RE:RE:RE:RE:RE:No follow through

RE:RE:RE:RE:RE:RE:RE:RE:No follow throughIn considering Sernova’s history of hanging on to news for dear life, I’d say to write the halt idea off as a “cute” halfwit Matthews stunt. A halt to me would appear cheap as I see it if it’s trial news that is involved. Even if a trial subject was proven to be insulin independent then release the news and Let ‘er Rip. 

Maybe be a different story for news of a collaboration if Sernova can negotiate cash out of pharma for the deal. 

an opinion
<< Previous
Bullboard Posts
Next >>